Risk Factors for Contrast-Induced Nephropathy

Omer Toprak\textsuperscript{a,}\textsuperscript{b} Mustafa Cirit\textsuperscript{a}

\textsuperscript{a}Department of Nephrology, Atatürk Training and Research Hospital, Izmir, Turkey; \textsuperscript{b}Division of Nephrology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn., USA

Key Words
Contrast media, nephropathy \cdot Contrast-induced nephropathy \cdot Coronary angiography, contrast-induced nephropathy \cdot Risk factors, contrast-induced nephropathy

Abstract
An increasing number of diagnostic imaging and interventional procedures require the use of radiographic contrast agents which has led to a parallel increase in the incidence of contrast-induced nephropathy (CIN). CIN is a serious clinical problem associated with increased morbidity and mortality, particularly in patients with chronic renal failure (see the Case Report). A key step to minimize CIN is to identify patients at risk of CIN. The aim of the present review was to summarize the knowledge about the risk factors of CIN, including the review of ultimate clinical research and developments.

Case Report
A 75-year-old female patient with a history of type 2 diabetes mellitus, congestive heart failure, hypertension, and chronic renal failure with an estimated glomerular filtration rate of 40 ml/min (baseline serum creatinine level 1.5 mg/dl) was admitted to the hospital with acute myocardial infarction. She underwent emergency cardiac catheterization. Before coronary angiography, the patient received orally 600 mg N-acetylcysteine and intravenously normal saline at 150 ml/h. Two days later, the serum creatinine level increased to 4.8 mg/dl, and the urine output decreased to 1,000 ml/day. The patient's creatinine level increased to 5.6 mg/dl on the 5th day after cardiac catheterization. The diagnosis was contrast-induced nephropathy. After nephrology consultation, the patient underwent hemodialysis for two sessions. The creatinine level returned to baseline values over the next several days without need for hemodialysis. The hospital stay was approximately 8 days longer and the hospital care cost almost fourfold higher than in other patients.

Definition and Incidence of CIN
The term CIN indicates an impairment of the renal function occurring within 3 days after intravascular administration of CM in the absence of an alternative etiol-
ogy. According to the guidelines of the European Society of Urogenital Radiology, elevation of the serum creatinine level by \( \geq 0.5 \text{ mg/dl} \) or \( \geq 25\% \) within 3 days of CM injection is defined as CIN [6]. Typically, the serum creatinine level begins to increase 24–72 h after the administration of CM, peaks at 3–5 days, and usually returns to baseline values within 2 weeks. Serum creatinine is the standard marker to detect CIN. However, serum creatinine demonstrates major limitations. Serum cystatin C is a useful detection marker of acute renal failure and may indicate CIN 1–2 days earlier than creatinine [7]. Cystatin C has been found to reflect changes in glomerular filtration rate (GFR) more rapidly than does serum creatinine, and it has been proposed as an alternative endogenous marker of GFR, showing a higher correlation with creatinine, and it has been proposed as an alternative endogenous marker of GFR, showing a higher correlation with standard clearance methods such as inulin or iohexol clearance [8]. The incidence of CIN is usually <2% in patients who do not have any risk factor for CIN, but the incidence can be increased to 90% in patients at high risk of CIN [3, 9, 10].

### Pathophysiology of CIN

CIN is mediated predominantly by outer medullary hypoxic tubular damage, probably combined with and accentuated by endothelial dysfunction and renal microcirculatory alterations [11–14]. Altered protective mechanisms also bring about the susceptibility to develop CIN in high-risk patients. Indeed, predisposing risk factors, such as preexisting renal dysfunction, diabetes, and congestive heart failure, are all characterized by compromised medullary oxygen sufficiency, related to defective nitric-oxide-dependent renal vasodilatation or prostaglandin synthesis, by increased reabsorptive work load, by enhanced systemic vasoconstrictive stimuli, or by structural changes of the renal microcirculation [14]. Tubular obstruction, direct toxic effects of the dye because of apoptosis, and oxidative damage may also play a role [5].

### Clinical Course and Outcomes

CIN is independently associated with increased in-hospital and long-term mortality and increases the costs of medical care by at least extending the hospital stay. Approximately USD 180 million is spent annually to manage CIN in the USA [1]. CIN may range in severity from asymptomatic, nonoliguric transient renal dysfunction to oliguric severe renal failure that necessitates permanent dialysis or kidney transplantation. CIN is reported to be the third leading cause of acute renal failure [1, 2]. Dangas et al. [15] showed that in-hospital outcome rates, such as of death (6.3 vs. 0.8%), cardiac death (4.0 vs. 0.5%), coronary artery bypass grafting (5.8 vs. 0.5%), major adverse cardiac events (9.3 vs. 1.1%), packed red cell transfusions (28 vs. 6%), vascular surgery of access site (5.6 vs. 2.6%), and postprocedure length of stay (6.8 ± 7.1 vs. 2.3 ± 2.5 days), were significantly higher in patients who developed CIN as compared with control patients (\( p < 0.0001 \)). In a cumulative 1-year outcome analysis, hospital death, out-of-hospital death, and major adverse cardiac event rates were significantly higher in patients who developed CIN (\( p < 0.0001 \)) [15]. A study of patients with acute myocardial infarction who underwent primary angioplasty showed that those who developed CIN had a significantly higher incidence of high-rate atrial fibrillation (\( p = 0.01 \)), high-degree conduction disturbances requiring a permanent pacemaker (\( p = 0.04 \)), acute pulmonary edema (\( p = 0.008 \)), respiratory failure requiring mechanical ventilation (\( p < 0.0001 \)), cardiogenic shock requiring an intra-aortic balloon (\( p < 0.0001 \)), and acute renal failure requiring renal replacement therapy (\( p < 0.0001 \)) [16]. In a retrospective analysis of 16,248 patients who underwent CM examinations, the in-hospital mortality rates were almost fivefold higher [34 vs. 7%; odds ratio (OR) = 6.5, \( p < 0.01 \)] in CIN patients, and CIN was associated with sepsis, bleeding, coma, or respiratory failure [17]. In all the CIN studies, 0.3–4% of the patients required short-term hemodialysis. Renal failure requiring dialysis after coronary interventions is associated with a 36% in-hospital mortality rate and has a 2-year mortality rate of 81% [1].

### Prevention Strategies

The treatment of established CIN is limited to supportive measures and dialysis. For this reason, screening for high-risk patients before CM-including cardiac procedures and taking the appropriate prophylactic regimens are important in reducing CIN. Patients at risk of CIN can often be identified on the basis of routine medical history, physical examination, and laboratory analysis before the procedure. Identifying patients with renal insufficiency is the main goal. After the high-risk patient population has been identified and risk factors addressed, the next step in preventing CIN is the use of different prophylactic measures. Therapies that have been studied for the prevention of CIN include vasodilators, antioxidants, and inhibitors of apoptosis, and oxidative damage may also play a role.
of CIN include saline hydration, sodium bicarbonate, N-acetylcysteine, theophylline, calcium channel blockers, diuretics, dopamine, endothelin antagonists, atrial natriuretic peptide, fenoldopam, captopril, prostaglandin E₁, ascorbic acid, hemodialysis after CM administration, or hemofiltration during and after CM administration [18–21]. Of all these measures, extracellular volume expansion with intravenous saline or sodium bicarbonate (0.9% saline might be more beneficial than 0.45% saline), minimizing the dose of CM, using low-osmolar nonionic CM instead of high-osmolar ionic CM, stopping the intake of nephrotoxic drugs, such as diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), and cyclooxygenase-2 (COX-2) inhibitors, and avoiding short intervals between procedures requiring CM have all been shown to be effective in reducing CIN. Alternatives to ordinary CM, such as carbon dioxide or gadolinium chelates, can be used in patients at high risk of developing CIN. Gadolinium seems to be as nephrotoxic as iodine-based CM, even when used for angiographic magnetic resonance imaging procedures in patients with renal failure [22, 23]. More studies need to be done to better understand the effects of gadolinium-based CM on CIN. Ultrasound contrast agents are microbubbles that produce acoustic enhancement, and they are pharmacologically almost inert and safe [24].

The protective role of acetylcysteine, which has been demonstrated by several recent clinical trials, may warrant its use in high-risk patients [19]. However, the administration of N-acetylcysteine in at-risk patients might theoretically reduce the incidence of CIN, but this finding has not been uniform or always demonstrated by currently published trials [20, 25].

**Risk Factors for CIN**

Specific factors that increase the risk of developing CIN are related to the patient, the CM, and the procedure [26–28]. Mehran et al. [27] developed a simple scoring method that integrates eight baseline clinical variables to assess the risk of CIN after percutaneous coronary intervention (PCI). These are hypotension (score 5), the use of an intra-aortic balloon pump (score 5), congestive heart failure (score 5), a serum creatinine level >1.5 mg/dl (score 4), age >75 years (score 4), anemia (score 3), diabetes mellitus (score 3), and the volume of CM (score 1/100 ml). If the total score is 5 or less, the risk category is low; if the total score is 16 or higher, the risk category is very high.

**Patient-Related Risk Factors**

The incidence of CIN is highly dependent on the clinical characteristics of the patients. An overview of the most common patient-related risk factors is given in tables 1–3.

**Older Age**

The possible reasons for the high incidence of CIN in elderly patients are age-related changes, such as a dominance of renal vasoconstrictive forces as opposed to renal vasodilatory forces, more difficult vascular access because of tortuosity, calcification of vessels requiring greater amounts of CM, defective prostaglandin synthesis, a decline in prostaglandin E₂, and the presence of renovascular diseases [2, 13, 29]. Furthermore, hypovolemia is very common in elderly patients who undergo diagnostic procedures. In a prospective study, in which elderly patients (≥70 years) were subjected to cardiac catheterization, 11% developed CIN [9]. In another study [30], the CIN incidence was 17% in elderly patients (≥60 years) as compared with 4% in younger patients. Marenzi et al. [16] showed that in 208 patients with acute myocardial infarction, who underwent coronary intervention, an age of 75 years or more was an independent risk factor for CIN (OR = 5.28, p = 0.0009).

**Gender**

Ovarian hormones can affect renin-angiotensin system and renal blood flow [31]. In a retrospective study of 8,628 patients who underwent PCI [32], female sex was an independent predictor of CIN (OR = 1.4, p < 0.0001). One-year outcome analyses by gender showed a higher mortality among females than among males in a cohort of CIN patients (14 vs. 10%, p = 0.05) [32]. The findings of this study contradict those of a previous randomized controlled trial of ionic versus nonionic CM, in which multivariate analysis identified male gender as an independent risk factor for CIN [33]. Whether female gender is truly an independent predictor of CIN will require further confirmatory studies.

**Preexisting Renal Disease**

A major risk factor for CIN is a GFR <60 ml/min/1.73 m² [1, 26, 27]. Cystatin C is a good GFR marker in cardiologic patients with earlier detection of mild renal dysfunction and allowing a better identification of patients with increased overall risk and those with chance of CM damage [7, 8]. Chronic kidney disease is associated with a decreased vasodilatory response which is impor-
Risk Factors for Contrast-Induced Nephropathy

In developing CIN, and in patients with renal insufficiency, the clearance of CM is slower than in normal subjects. In a study of 7,586 patients who underwent coronary intervention [10], CIN developed in 22.4% of those who had serum creatinine levels of 2.0–2.9 mg/dl and in 30.6% of those with serum creatinine levels of 3.0 mg/dl or higher as compared with 2.4% of the patients with serum creatinine levels <1.1 mg/dl. Moore et al. [34] and Barrett et al. [35] reported that the incidence of CIN increased from 4 to 20%, as the baseline serum creatinine level increased from 1.2 to 2.9 mg/dl. In another study [36], the incidence of CIN increased from 8 to 92%, as the serum creatinine concentration increased from 1.5 to 6.8 mg/dl. Furthermore, the probability of CIN requiring dialysis increased from 0.04 to 48%, as the baseline GFR decreased from 50 to 10 ml/min [36].

### Table 1. Patient-related confirmed risk factors for the development of CIN

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>OR (95% CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preexisting renal failure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preprocedural creatinine 2.0–2.9 mg/dl [10]a</td>
<td>7.37 (4.78–11.39)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Preprocedural creatinine ≥ 3 mg/dl [10]a</td>
<td>12.82 (8.01–20.54)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preprocedural creatinine ≤ 1.1 mg/dl [10]a</td>
<td>1.86 (1.20–2.89)</td>
<td>0.005</td>
</tr>
<tr>
<td>Preprocedural creatinine 1.2–1.9 mg/dl [10]a</td>
<td>2.42 (1.54–3.79)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age &gt;75 years [16]b</td>
<td>5.28 (1.98–14.05)</td>
<td>0.0009</td>
</tr>
<tr>
<td>Class III–IV congestive heart failure [28]c</td>
<td>2.20 (1.60–2.90)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Left ventricle ejection fraction ≤ 40% [15]d</td>
<td>1.57 (1.14–2.16)</td>
<td>0.005</td>
</tr>
<tr>
<td>Periprocedural hypotension [15]d</td>
<td>2.50 (1.70–3.69)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hypertension [28]c</td>
<td>2.00 (1.40–2.80)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Baseline hematocrit [15]d</td>
<td>0.95 (0.93–0.97)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Acute myocardial infarction ≤ 24 h [10]a</td>
<td>1.85 (1.31–2.63)</td>
<td>0.0006</td>
</tr>
<tr>
<td>Peripheral vascular disease [28]c</td>
<td>1.90 (1.40–2.70)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Use of ACE inhibitors [49]e</td>
<td>3.37 (1.14–9.94)</td>
<td>0.028</td>
</tr>
</tbody>
</table>

Confounding variables that were used in the multivariable logistic regression models were:

- **a** Total volume of CM, age, sex, body mass index, history of congestive heart failure, diabetes, hypertension, metastatic cancer, preprocedural shock, tumor, peptic ulcer disease, peripheral vascular disease, and myocardial infarction within 24 h before the procedure.
- **b** Age ≥ 75 years, anterior acute myocardial infarction, time to reperfusion ≥ 6 h, contrast agent volume ≥ 300 ml, and use of an intra-aortic balloon pump.
- **c** Creatinine clearance <60 ml/min, intra-aortic balloon pump use, urgence/emergency procedure, diabetes mellitus, congestive heart failure, hypertension, peripheral vascular disease, and contrast volume >260 ml.
- **d** Estimated GFR, age, female gender, diabetes, previous myocardial infarction, previous coronary artery bypass grafting, African-American race, previous coronary intervention, hypertension, myocardial infarction, stent used, left ventricular ejection fraction <40%, hyperlipidemia, peripheral arterial disease, history of stroke, body surface area, multivessel percutaneous coronary intervention, congestive heart failure, pulmonary edema on presentation, periprocedural hypotension, intra-aortic balloon pumping, baseline hematocrit, ioxaglate, and contrast/body surface area ratio.
- **e** Multivessel involvement, hypoalbuminemia, diabetes mellitus, GFR ≤ 40 ml/min, congestive heart failure, and chronic use of ACE inhibitors.

---

**Diabetes Mellitus**

Patients with diabetes constitute an important group at high risk of developing CIN. Nitric-oxide-dependent renal vasodilation is characteristically altered, and the renal outer medullary O₂ is significantly reduced in diabetes [14]. Chronic kidney disease and diabetes mellitus are associated with endothelial dysfunction and decreased vasodilatory responses. Diabetic nephropathy has been identified as a powerful and independent risk factor for CIN [1–3]. Patients with diabetic nephropathy and a mean serum creatinine level of 6.8 mg/dl had a 92% incidence of CIN after coronary angiography [37]. Patients with diabetes who have advanced chronic renal failure for causes other than diabetic nephropathy are at a significantly higher risk of developing CIN-like diabetic nephropathy. On the other hand, studies have shown that preex-
existing renal disease is present, patients with and without diabetes are similarly at risk of CIN which correlates with the degree of renal disease [36, 38]. Some authors have suggested that diabetes mellitus in the absence of nephropathy, particularly in insulin-dependent patients with diabetes, is associated with an increased risk of CIN. In a study performed by Lautin et al. [39], it was found that the incidence of CIN was rather low (2%) in patients with neither diabetes nor azotemia, significantly higher (16%) in individuals with diabetes but preserved renal function, and much higher (38%) in patients who had both diabetes and azotemia. In a study done by Rihal et al. [10], the incidence of CIN was found to be 2% in patients without diabetes and 3.7% in patients with diabetes with a baseline creatinine concentration of 1.1 mg/dl or less (OR = 1.86, p = 0.005). When the renal function is mildly impaired (serum creatinine level 1.2–1.9 mg/dl), the risk of CIN in patients with diabetes mellitus increases to 4.5% (OR = 2.42, p < 0.001) [10]. Other research has failed to detect this connection. For example, Parfrey et al. [40], in an earlier study of patients with diabetes, showed that none of the 85 patients with diabetes and a normal renal function developed clinically significant CIN. However, given that, those with diabetes alone were found to be at a slightly higher risk of developing CIN than the general population [2].

**Congestive Heart Failure and Reduced Left Ventricular Ejection Fraction**

Studies have shown that a reduced left ventricular ejection fraction (≤ 49%) and advanced congestive heart failure (New York Heart Association class III or IV) are independent risk factors for CIN [41, 42]. Dangas et al. [15] showed that a left ventricular ejection fraction <40% is an independent predictor of CIN. We have previously reported [43] that if the left ventricular ejection fraction is >30%, this condition does not show any significant effect on the development of CIN. Advanced heart failure and

---

**Table 2. Patient-related possible risk factors for the development of CIN**

<table>
<thead>
<tr>
<th>Factor</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypoalbuminemia</td>
<td>[9]</td>
</tr>
<tr>
<td>Structural kidney disease or damage</td>
<td>[1]</td>
</tr>
<tr>
<td>Female gender</td>
<td>[32]</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>[57]</td>
</tr>
<tr>
<td>Cirrhosis of the liver</td>
<td>[2]</td>
</tr>
<tr>
<td>Nephrotic syndrome</td>
<td>[1]</td>
</tr>
<tr>
<td>Diuretic usage</td>
<td>[12]</td>
</tr>
<tr>
<td>Sepsis</td>
<td>[2]</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>[53]</td>
</tr>
<tr>
<td>Hypertriglyceridemia</td>
<td>[71]</td>
</tr>
<tr>
<td>Use of nephrotoxic drugs</td>
<td>[50, 51]</td>
</tr>
<tr>
<td>Multivessel coronary involvement</td>
<td>[27]</td>
</tr>
<tr>
<td>Renal artery stenosis</td>
<td>[15]</td>
</tr>
<tr>
<td>Hyperuricemia</td>
<td>[61]</td>
</tr>
<tr>
<td>Proteinuria</td>
<td>[1]</td>
</tr>
<tr>
<td>Renal transplant</td>
<td>[67]</td>
</tr>
<tr>
<td>Pulmonary edema</td>
<td>[15]</td>
</tr>
<tr>
<td>Urine albumin-creatinine ratio &gt;30</td>
<td>[1]</td>
</tr>
<tr>
<td>Serum sodium &lt;135 mEq/l</td>
<td>[9]</td>
</tr>
<tr>
<td>Impaired fasting glucose</td>
<td>[71]</td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>[71]</td>
</tr>
<tr>
<td>Low effective circulatory volume</td>
<td>[10]</td>
</tr>
</tbody>
</table>

**Table 3. Prevention strategies for CIN in high-risk patients**

<table>
<thead>
<tr>
<th>Clinical evidence advocating the use of</th>
<th>Do not give</th>
<th>Therapies with conflicting or limited evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extracellular volume expansion</td>
<td>NSAIDs, COX-2 inhibitors, aminoglycoside, cisplatin, etc.</td>
<td>acetylcysteine</td>
</tr>
<tr>
<td>Isotonic saline (sodium chloride or sodium bicarbonate)</td>
<td>loop diuretics</td>
<td>theophylline</td>
</tr>
<tr>
<td>Low- or isoosmolar CM</td>
<td>mannitol</td>
<td>atrial natriuretic peptide</td>
</tr>
<tr>
<td>Minimizing the dose of CM</td>
<td>multiple CM within 72 h</td>
<td>prostaglandin E₁</td>
</tr>
<tr>
<td>Alternative imaging techniques</td>
<td>large doses of CM</td>
<td>calcium channel blockers</td>
</tr>
<tr>
<td>Creatinine measurement before and 48 h after the procedure</td>
<td>high-osmolar CM</td>
<td>captopril</td>
</tr>
<tr>
<td>CM delayed until the hemodynamic status is corrected</td>
<td>metformin, especially in renal failure patients</td>
<td>fenoldopam endothelin antagonists ascorbic acid hemofiltration</td>
</tr>
</tbody>
</table>

---

Risk Factors for Contrast-Induced Nephropathy

Hypertension

An explanation for hypertension as a risk factor for CIN is that alterations in the intrarenal expression of vasoactive mediators, such as the renin-angiotensin system or nitric oxide, may be contributing factors. An impaired nitric-oxide-dependent renal vasodilation is prevalent in individuals who are hypertensive. Finally, a reduced number of nephrons could predispose hypertensive patients to CIN. Hypertension has been categorized as a risk factor for CIN in some research. In a study of 8,628 patients who underwent PCI [32], hypertension was found to be an independent predictor of CIN (OR = 1.2, p = 0.0035). In a cohort study, Bartholomew et al. [28] found that hypertension is a risk for CIN in patients who underwent PCI (OR = 2.0, p = 0.0001).

Angiotensin-Converting Enzyme (ACE) Inhibitors

In some studies [44], ACE inhibitors have been identified as risk factors for CIN because of their potential to reduce the renal function. Some studies have shown that the nephrotoxicity of CM may be reduced because of decreased renal vasoconstriction by inhibition of angiotensin II. Caldicott et al. [45] showed that renal vasoconstriction occurs after CM administration and that the renin-angiotensin system is responsible for this vasoconstriction. In another study performed in animals after CM administration [46], there was no significant change in angiotensin II and renin levels. It was found that the suppression of prostacyclin contributed to the renal function changes rather than the activation of the renin-angiotensin system. In a randomized controlled study with 71 patients having diabetes who underwent coronary angiography and were randomized to captopril treatment or the control group [47], 25 mg captopril was given three times daily. There was a significant decrease in CIN in the patients who received captopril as compared with the control group (6 vs. 29%, respectively; p < 0.02). We have previously performed a randomized controlled study in 80 patients with a serum creatinine level <2 mg/dl who underwent coronary angiography [48]. Captopril was administered to 48 patients before coronary angiography. Five patients (10.4%) in the captopril group developed CIN as compared with only 1 patient (3.1%) in the control group (p = 0.02). In a recent study done in 230 patients with renal insufficiency and an age ≥65 years [49], we found that chronic ACE inhibitor administration was a risk factor for developing CIN. CIN occurred in 17 patients (15.6%) of the ACE inhibitor group and in 7 patients (5.8%) of the control group (p = 0.015). The serum creatinine level increased from 1.34 ± 0.20 to 1.53 ± 0.27 mg/dl in the ACE inhibitor group and from 1.33 ± 0.18 to 1.45 ± 0.19 mg/dl in the control group (p < 0.001). Chronic ACE inhibitor administration was a risk indicator of CIN (OR = 3.37, p = 0.028). Checking the use of ACE inhibitors before coronary angiography seems to be useful in the risk assessment for CIN. It is reasonable to suggest that there is a need to hold ACE inhibitor use before coronary angiography.

Nephrotoxic Drugs

Nephrotoxic drugs and those that inhibit the vasodilatory effects of prostaglandins have been reported to render the kidney more vulnerable to CM [50]. Sulfonamides, aminoglycosides, and their combination with furosemide are particularly potent. Ciclosporin A may intensify medullary hypoxia, and cisplatin can attach to sulphhydryl groups. Mannitol can increase the metabolic work load in the kidney, and amphotericin B can cause the effect of a combination of mannitol and ciclosporin A. However, the individual roles of these medications as independent risk factors of CIN have not been determined in large clinical trials [2]. Nonetheless, it seems quite likely that nonselective NSAIDs and selective COX-2 inhibitors decrease the generation of vasodilatory prostaglandins in the kidney and potentiate the vasoconstrictive effects of CM [51].

Multiple Myeloma

Multiple myelomas have been suggested as potential risk factors for CIN, on the basis of initial reports. The pathomechanism of this process has been explained by the precipitation of CM molecules together with Tamm-Horsfall proteins and other abnormal proteins, tubular epithelial cells damaged and desquamated as a result of ischemia, direct contrast toxicity, or disturbed function of integrins. In studies conducted in animals, intratubular light chains, particularly in the setting of intravascular volume depletion, have been found to augment the nephrotoxic potential of CM [52, 53]. Studies with a broader
scope have since shown that the observed risk is linked to coexisting risk factors, such as preexisting renal insufficiency, low circulating volume, proteinuria, amyloidosis, hyperuricemia, and hypercalcemia, rather than to the myeloma itself [2]. Retrospective studies showed an incidence of CIN of only 0.6–1.25% in patients with myelomas, if dehydration is avoided [54].

**Metformin**

The oral antidiabetic agent metformin is not itself nephrotoxic, but it is known that patients who are receiving metformin may develop lactic acidosis as a result of CIN. A decline in renal function after CM exposure could adversely affect the clearance of metformin. This complication was almost always observed in diabetic patients with decreased renal function before injection of CM. A meta-analysis by the Cochrane Library with pooled data from 176 comparative trials and cohort studies [55] revealed no cases of fatal or nonfatal lactic acidosis in 35,619 patient years of metformin use or in 30,002 patients years in the nonmetformin group. It seems safer and reasonable to instruct patients especially at high risk of developing CIN not to take this drug for 48 h or so after CM and to resume taking the drug only, if there are no signs of nephrotoxicity [6, 38, 56].

**Hypercholesterolemia**

In the literature, there are only two experimental studies on the relationship between hypercholesterolemia and CIN. According to these studies, hypercholesterolemia aggravates CIN through the reduced production of nitric oxide. Altered nitric-oxide-dependent renal vasodilation, which is important in the pathogenesis of CIN, is prevalent in hypercholesterolemia [57, 58].

**Hyperuricemia**

It has been suggested that tubular obstruction by uric acid plays a role in the pathogenesis of CIN. CM have a uricosuric effect which appears to be caused by enhanced renal tubular secretion of uric acid [59]. Furthermore, hyperuricemia is accompanied by an enhanced synthesis of reactive oxygen species, an activated renin-angiotensin-aldosterone system, increased endothelin-1 levels, and an inhibited nitric oxide system which play a role in the pathogenesis of CIN [60]. In a recent prospective cohort study [61], we evaluated 266 patients who underwent elective coronary angiography, and we found that patients with hyperuricemia are at risk of developing CIN (OR = 4.71, p = 0.019). CIN occurred in 15.1% of the hyperuricemic group and in 2.9% of the normouricemic group (p < 0.001). Longer hospital stays (p < 0.001) and CIN requiring renal replacement therapy (p = 0.017) were significantly more prevalent in the hyperuricemic group. Serum uric acid levels ≥7 mg/dl in males and ≥5.9 mg/dl in females were found to be the best cutoff values for the prediction of CIN [61].

**Multivessel Coronary Involvement, Peripheral Vascular Disease, and Renal Artery Stenosis**

Factors related to accelerated or diffuse atherosclerosis are linked to the development of CIN [15]. The treatment of multivessel disease, challenging chronic total occlusions and extensively diseased coronary segments, may require high doses of CM for providing an optimal image quality, thus enhancing the potential toxic effects on the renal function. If a patient has multivessel coronary involvement, the other vessels in the body, such as the renal artery, can be involved. If the renal artery is involved, the renal blood supply may decrease, and the kidneys may be more susceptible to CIN. In a study of 177 patients who underwent cardiac catheterization [62], they were also evaluated for renal artery stenosis. Coronary artery disease was detected in 110 patients (62%), and significant renal artery stenosis was detected in 19 patients (11%). Using multivariate analysis, it was found that the extent of coronary artery disease was an independent predictor of renal artery stenosis [62]. We found only one study that evaluated multivessel coronary involvement as a risk predictor of CIN in addition to the well-known CIN risk factors. A total of 5,571 patients who underwent PCI were evaluated for CIN risk factors, and it was found that multivessel coronary involvement was only a univariate predictor of CIN (p = 0.003) [27]. In a cohort study by Bartholomew et al. [28] and in another study by Rihal et al. [10], it was found that peripheral vascular disease is a risk for CIN in patients who underwent PCI (OR = 1.9, p < 0.0001, and OR = 1.71, p = 0.001, respectively).

**Hypovolemia**

Decreased effective circulating volume and reduced renal perfusion potentiate renal vasoconstriction after administration of intravascular CM [52, 63, 64]. Hypovolemia leads to active sodium reabsorption, which is an oxygen-demanding process, and increases neurohumoral vasoconstrictive stimuli that might compromise medullary oxygenation [14]. The toxic effects of CM on the renal tubular lumen may be exacerbated in hypovolemia [65]. Upon injection of CM, fluid shifts from tissues into the vascular system, and this leads to a decreased circulating volume. Volume expansion reduces the activity of the re-
Risk Factors for Contrast-Induced Nephropathy

Renal Transplantation

Patients with renal transplantation may be at a higher risk of developing CIN due to the concomitant use of ciclosporin and the higher prevalence of diabetes and renal insufficiency. Ahuja et al. [67] studied 33 patients with a functioning renal allograft who underwent different CM studies, and the incidence of CIN was 21.2%.

Acute Myocardial Infarction

A study performed by Rihal et al. [10] showed that acute myocardial infarction within 24 h before administration of the CM is a risk factor for CIN (OR = 1.85, p = 0.0006). This study demonstrated that CIN is a frequent complication in acute myocardial infarction, even in patients with a normal baseline renal function. Marenzi et al. [16] showed that in 208 acute myocardial infarction patients who underwent primary PCI, the incidence of anterior acute myocardial infarction was significantly higher in patients who developed CIN (p = 0.0015). However, in multivariate analysis, anterior acute myocardial infarction (OR = 2.17, p = 0.09) was not a risk predictor of CIN [16]. In 2,082 PCIs for acute myocardial infarction, Sadeghi et al. [68] reported a more than sevenfold (3.2 vs. 23.3%) increase in the 1-year mortality in patients who developed CIN.

Low Hematocrit Level

Anemia-induced deterioration of renal ischemia may be one plausible explanation for the higher incidence of CIN in patients with a low hematocrit level. A baseline hematocrit value <39% for men and <36% for women is a risk for developing CIN [1]. The relationship between low hematocrit levels and CIN has been investigated by Nikolsky et al. [69] in a prospective study of 6,773 patients who underwent PCI. A lower baseline hematocrit was an independent predictor of CIN, and each 3% decrease in baseline hematocrit resulted in a significant increase in the odds of CIN in patients with and without chronic kidney disease (11 and 23%, respectively). Dangas et al. [15] showed that the baseline hematocrit level is an independent predictor of CIN in patients with chronic kidney disease (OR = 0.95, p < 0.00001).

Low Serum Albumin Level

Hypoalbuminemia impairs the endothelial function, enhances the renal vasoconstriction, impairs the synthesis and release of nitric oxide, and decreases the antioxidant enzyme activity [70]. In the literature, we found only one study on the association between serum albumin and CIN. In this study [9], a low serum albumin concentration (<3.5 g/dl) was identified as a risk factor for CIN in patients 70 years of age or older who underwent cardiac catheterization.

Hypotension, Sepsis, Cirrhosis, and Pulmonary Edema

A systolic blood pressure <80 mm Hg for at least 1 h that requires inotropic support with medications is a risk factor for CIN [1]. A study performed by Dangas et al. [15] showed that periprocedural hypotension and pulmonary edema are independent predictors of CIN in patients with chronic kidney disease (OR = 2.50, p < 0.00001, and OR = 2.56, p = 0.001, respectively). Sepsis, through direct damage by bacterial toxins to renal tubules and impairment of the circulation, has also been reported as a risk factor [2]. Reduction of effective intravascular volume caused by liver cirrhosis has been reported as contributing to prerenal reduction in renal perfusion, thus enhancing the ischemic insult of CM [2].

Metabolic Syndrome, Impaired Fasting Glucose, and Hypertriglyceridemia

In a recent prospective cohort study of 219 nondiabetic elderly patients with reduced kidney function who underwent elective coronary angiography [71], we reported that metabolic syndrome was a risk indicator of CIN (OR = 4.26, p = 0.026). CIN occurred in 14% of the patients of the metabolic syndrome group and in 3.6% of those of the nonmetabolic syndrome group (relative risk 3.93, p = 0.007). Impaired fasting glucose (OR = 4.72, p = 0.007), high triglyceride levels (OR = 4.06, p = 0.022), and multivessel involvement (OR = 3.14, p = 0.038) in the metabolic syndrome group were predictors of CIN [71].

Procedure- and Contrast-Agent-Related Risk Factors

The most common risk factors for developing CIN are (1) a high total dose of CM [72]; (2) a high osmolality of the CM [13]; (3) a high ionic content of the CM [33, 73];
REFERENCES


Acknowledgments

This study was supported by a grant from the Turkish Society of Nephrology. We would like to express our deep appreciation to Dr. Alp Ikizler, Division of Nephrology, Vanderbilt University School of Medicine, Nashville, Tenn., USA, for his insight and editorial assistance.
Risk Factors for Contrast-Induced Nephropathy